$MBRX

Moleculin Biotech (MBRX) shares dropped 25% after interim trial data for Annamycin in AML patients showed no statistical significance, though remission rates were higher than standard chemotherapy. The MIRACLE trial continues with 67 of 90 patients enrolled. The company has $10.317M in cash, expected to last until Q3 2026. CEO Klemp called results encouraging but noted more data is needed.

Walter V. Klemp, CEO of Moleculin Biotech (MBRX), disclosed a 9.87% stake in the company's common stock via a Schedule 13D filing on Aug. 25, 2026. He acquired shares and warrants in an Aug. 3, 2026 public offering and has the option to increase his ownership to 9.99%. Klemp may adjust his position and consider strategic transactions in the future.

Moleculin Biotech (MBRX) CFO Jonathan Foster invested $220K in the company's stock and warrants, acquiring 293,333 shares and warrants for 879,999 more. The purchase was part of a public offering, with funds from personal savings. Foster may increase his stake or change investment plans. He also participated in preparing proposals for the 2026 annual meeting, including a reverse stock split.

Moleculin Biotech (MBRX) CEO Walter Klemp invested $400K in the company's public offering, purchasing 533,333 shares and warrants for 1.6M more shares at $0.75 each. AnnaMed, a holding company, also owns 636 shares. Klemp plans to invest further, reserving the right to acquire or dispose of more securities.

Moleculin Biotech (Nasdaq: MBRX) reported preliminary unblinded interim efficacy from its MIRACLE pivotal AML trial on Aug. 14. In 45 patients, complete remission rates were 43% and 36% for Annamycin 190 and 230 mg/m² plus cytarabine versus 12% in control; composite CRc was 50% and 57% versus 29%. Company reported no cardiotoxicity to date and said cash was about $7.3M at June 30, 2026.

Moleculin Biotech reported a Q2 2026 net loss of $7.6M and a loss per share of $1.40, narrowing from $12.25 per share in Q2 2025. The company had no revenue and reported 36 MIRACLE trial enrollments in Part A at quarter end. Wall Street consensus listed 6 buys, 1 hold, and 0 sells.

Moleculin Biotech, Inc. (MBRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Moleculin Biotech Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of Pivotal MIRACLE Trial - Positive interim MIRACLE data showed complete remission rates three times higher than control in relapsed/refractory AML - MIRACLE trial ad

Foster Jonathan P. (Chief Financial Officer) purchased 293,333 shares of Moleculin Biotech, Inc. (MBRX) on 2026-08-03.

PICKER DONALD H (Chief Science Officer) purchased 173,333 shares of Moleculin Biotech, Inc. (MBRX) on 2026-08-03.

Moleculin Biotech reported interim blinded Part A data from its MIRACLE Phase II/III trial of Annamycin plus cytarabine (AnnAraC) in relapsed or refractory AML. In 62 evaluable patients, CR was 24% and CRc 37%. Among 30 prior venetoclax-failure patients, results were in a harder-to-treat group. Part A has 74/90 enrolled, completion expected by Sep 2026, unblinded results Dec 2026-Feb 2027.